Stocks
Eli Lilly and Company Financial Statements (LLY) |
||||||||||
| Eli Lilly and Companysmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 19.02.2020 | 17.02.2021 | 23.02.2022 | 22.02.2023 | 21.02.2024 | 30.04.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 22 320 | 24 540 | 28 318 | 28 541 | 34 124 | 35 932 | |||
| Operating Income, bln rub | 4 974 | 6 058 | 6 357 | 7 127 | 10 325 | 8 274 | ||||
| EBITDA, bln rub | ? | 6 605 | 7 641 | 8 739 | 9 434 | 12 456 | 15 535 | |||
| Net profit, bln rub | ? | 4 638 | 6 194 | 5 582 | 6 245 | 5 240 | 6 138 | |||
| OCF, bln rub | ? | 4 837 | 6 500 | 7 261 | 7 084 | 4 240 | 3 676 | |||
| CAPEX, bln rub | ? | 1 354 | 2 029 | 1 873 | 2 484 | 7 392 | 7 475 | |||
| FCF, bln rub | ? | 3 483 | 4 471 | 5 388 | 4 600 | -3 152 | -3 799 | |||
| Dividend payout, bln rub | 2 410 | 2 687 | 3 087 | 3 536 | 4 069 | 4 221 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 52.0% | 43.4% | 55.3% | 56.6% | 77.7% | 68.8% | ||||
| OPEX, bln rub | 11 809 | 12 207 | 13 458 | 13 631 | 17 223 | 17 725 | ||||
| Cost of production, bln rub | 4 721 | 5 483 | 7 313 | 6 630 | 6 576 | 6 861 | ||||
| R&D, bln rub | 5 595 | 6 086 | 7 026 | 7 191 | 9 313 | 9 851 | ||||
| Interest expenses, bln rub | 400.6 | 359.6 | 339.8 | 331.6 | 312.3 | 472.4 | ||||
| Assets, bln rub | 39 286 | 46 633 | 48 806 | 49 490 | 64 006 | 63 944 | ||||
| Net Assets, bln rub | ? | 2 607 | 5 642 | 8 979 | 10 650 | 10 772 | 12 812 | |||
| Debt, bln rub | 15 804 | 16 595 | 16 885 | 16 239 | 25 225 | 26 211 | ||||
| Cash, bln rub | 2 439 | 3 681 | 3 909 | 2 212 | 2 928 | 2 586 | ||||
| Net debt, bln rub | 13 365 | 12 914 | 12 976 | 14 027 | 22 298 | 23 625 | ||||
| Ordinary share price, rub | 131.4 | 168.8 | 276.2 | 365.8 | 582.9 | 579.6 | ||||
| Number of ordinary shares, mln | 931.1 | 907.6 | 907.0 | 901.7 | 900.2 | 900.8 | ||||
| Market cap, bln rub | 122 369 | 153 245 | 250 521 | 329 891 | 524 734 | 522 104 | ||||
| EV, bln rub | ? | 135 734 | 166 159 | 263 497 | 343 918 | 547 031 | 545 729 | |||
| Book value, bln rub | -7 691 | -5 575 | -2 605 | -630 | -1 074 | 1 110 | ||||
| EPS, rub | ? | 4.98 | 6.82 | 6.15 | 6.93 | 5.82 | 6.81 | |||
| FCF/share, rub | 3.74 | 4.93 | 5.94 | 5.10 | -3.50 | -4.22 | ||||
| BV/share, rub | -8.26 | -6.14 | -2.87 | -0.70 | -1.19 | 1.23 | ||||
| EBITDA margin, % | ? | 29.6% | 31.1% | 30.9% | 33.1% | 36.5% | 43.2% | |||
| Net margin, % | ? | 20.8% | 25.2% | 19.7% | 21.9% | 15.4% | 17.1% | |||
| FCF yield, % | ? | 2.85% | 2.92% | 2.15% | 1.39% | -0.60% | -0.73% | |||
| ROE, % | ? | 177.9% | 109.8% | 62.2% | 58.6% | 48.6% | 47.9% | |||
| ROA, % | ? | 11.8% | 13.3% | 11.4% | 12.6% | 8.19% | 9.60% | |||
| P/E | ? | 26.4 | 24.7 | 44.9 | 52.8 | 100.1 | 85.1 | |||
| P/FCF | 35.1 | 34.3 | 46.5 | 71.7 | -166.5 | -137.4 | ||||
| P/S | ? | 5.48 | 6.24 | 8.85 | 11.6 | 15.4 | 14.5 | |||
| P/BV | ? | -15.9 | -27.5 | -96.2 | -523.8 | -488.4 | 470.2 | |||
| EV/EBITDA | ? | 20.6 | 21.7 | 30.2 | 36.5 | 43.9 | 35.1 | |||
| Debt/EBITDA | 2.02 | 1.69 | 1.48 | 1.49 | 1.79 | 1.52 | ||||
| R&D/CAPEX, % | 413.4% | 299.9% | 375.1% | 289.5% | 126.0% | 131.8% | ||||
| CAPEX/Revenue, % | 6.06% | 8.27% | 6.61% | 8.70% | 21.7% | 20.8% | ||||
| Eli Lilly and Company shareholders | ||||||||||
